Therapeutic approaches for refractory germ cell cancer
Standard
Therapeutic approaches for refractory germ cell cancer. / Oing, Christoph; Seidel, Christoph; Bokemeyer, Carsten.
in: EXPERT REV ANTICANC, Jahrgang 18, Nr. 4, 04.2018, S. 389-397.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Therapeutic approaches for refractory germ cell cancer
AU - Oing, Christoph
AU - Seidel, Christoph
AU - Bokemeyer, Carsten
PY - 2018/4
Y1 - 2018/4
N2 - INTRODUCTION: Most germ cell cancer patients with metastatic disease are cured by cisplatin-based combination chemotherapy. 30% of metastatic patients will develop relapse or progress despite adequate first-line treatment and will require salvage therapy, with about 10% of metastasized patients ultimately developing platinum-resistant and fatal disease. Areas covered: Based on a comprehensive literature search of MEDLINE, EMBASE and conference proceedings of ESMO, ASCO and EAU meetings, this review provides an overview on current and potential future treatment options for platinum-refractory germ cell cancer patients including cytostatics and molecularly targeted therapies. Expert commentary: Treatment of platinum-refractory disease remains challenging and long-term survival is rarely achieved despite multimodal treatment approaches. Targeted treatment approaches do not yet play a role in the treatment of platinum-refractory disease due to lacking efficacy in small, unselected clinical trials. Inclusion of patients into clinical trials is strongly recommended.
AB - INTRODUCTION: Most germ cell cancer patients with metastatic disease are cured by cisplatin-based combination chemotherapy. 30% of metastatic patients will develop relapse or progress despite adequate first-line treatment and will require salvage therapy, with about 10% of metastasized patients ultimately developing platinum-resistant and fatal disease. Areas covered: Based on a comprehensive literature search of MEDLINE, EMBASE and conference proceedings of ESMO, ASCO and EAU meetings, this review provides an overview on current and potential future treatment options for platinum-refractory germ cell cancer patients including cytostatics and molecularly targeted therapies. Expert commentary: Treatment of platinum-refractory disease remains challenging and long-term survival is rarely achieved despite multimodal treatment approaches. Targeted treatment approaches do not yet play a role in the treatment of platinum-refractory disease due to lacking efficacy in small, unselected clinical trials. Inclusion of patients into clinical trials is strongly recommended.
KW - Journal Article
U2 - 10.1080/14737140.2018.1450630
DO - 10.1080/14737140.2018.1450630
M3 - SCORING: Review article
C2 - 29516750
VL - 18
SP - 389
EP - 397
JO - EXPERT REV ANTICANC
JF - EXPERT REV ANTICANC
SN - 1473-7140
IS - 4
ER -